Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (22245)	6/15/1998 6:12:00 AM
From: Henry Niman	Respond to of 32384

Ralf, LGND has not funded its pipeline through the selling of equity issues to the public. They have only done one secondary (in 1996) although they did sell ALRIZ (in 1995). LGND has indicated that they do not expect to do another follow on. They have targeted next year for profitability and finance their pipeline through alliances (an I would expect more there). ONTAK should be their first "in-house" product (although it was developed by SRGN - LGND will get the lion's share of the profits if the acquisition is approved) and LGND expects to generate a significant income by charging $40,000 for a treatment course for CTCL as well as off label use (for cancers such as non-Hodgkins lymphoma).